The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Fulcrum Therapeutics, Inc(NASDAQ:FULC) 
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is i...
Website: http://www.fulcrumtx.com
Founded: 2015
Full Time Employees: 73
CEO: Robert J. Gould
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Fulcrum Therapeutics Days Payable Outstanding ttm (DPO)
Fulcrum Therapeutics Days Receivable Outstanding ttm (DSO)
Fulcrum Therapeutics Op Cashflow Per Share ttm
Fulcrum Therapeutics Free Cashflow Per Share ttm
Fulcrum Therapeutics Cash Per Share ttm
Fulcrum Therapeutics P/S ratio ttm
Fulcrum Therapeutics (GAAP) P/E ratio ttm
Fulcrum Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.